Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

2-Methoxyestradiol - CASI Pharmaceuticals

Drug Profile

2-Methoxyestradiol - CASI Pharmaceuticals

Alternative Names: 2ME2; CASI-2ME2; Panzem; Panzem® Capsules; Panzem® NCD

Latest Information Update: 24 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Childrens Hospital Boston; Harvard Medical School
  • Developer CASI Pharmaceuticals; EntreMed
  • Class Antineoplastics; Estradiol congeners; Estrenes; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Hypoxia-inducible factor-1 alpha inhibitors; Lymphocyte inhibitors; Mitosis inhibitors; NFATC transcription factor inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Ovarian cancer; Multiple myeloma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Autoimmune disorders; Rheumatoid arthritis
  • Discontinued Age-related macular degeneration; Breast cancer; Carcinoid tumour; Cardiovascular disorders; Endometriosis; Glioblastoma; Multiple myeloma; Osteoporosis; Ovarian cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 20 Jul 2015 Suspended - Preclinical for Autoimmune disorders in USA (PO) before July 2015
  • 27 Mar 2015 CASI Pharmaceuticals plans a phase I pharmacokinetic trial
  • 16 Jun 2014 EntreMed is now called CASI Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top